A Phase 1b, Open Label, Multicenter Study of Positron Emission Tomography With Computed Tomography (PET/CT) Using ⁸⁹Zr Df-IAB22M2C (CD8 PET/CT Tracer) in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Bempegaldesleukin (Primary) ; Crefmirlimab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Nektar Therapeutics
- 14 Jul 2021 New trial record